Analyst Reco. QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 20:00:00 16/03/2026 GMT			5-day change	1st Jan Change
17.65 ^USD	+3.22%		-11.13%	-38.20%

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-13	Joseph M. Busky to Retire as Principal Financial Officer of Quidelortho Corporation, Effective as of June 30, 2026	CI

Analyst Reco.

02-12	UBS Adjusts QuidelOrtho Price Target to $30 From $35, Maintains Neutral Rating	MT
01-21	UBS Adjusts QuidelOrtho Price Target to $35 From $31, Maintains Neutral Rating	MT
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
11-03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
07/10/25	Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40	MT
03/09/25	RBC Raises Price Target on QuidelOrtho to $62 From $60, Keeps Outperform Rating	MT
07/08/25	UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating	MT
08/05/25	UBS Cuts Price Target on QuidelOrtho to $29 From $45, Keeps Neutral Rating	MT
13/02/25	UBS Raises Price Target on QuidelOrtho to $45 From $43, Maintains Neutral Rating	MT
13/02/25	RBC Trims Price Target on QuidelOrtho to $61 From $64, Keeps Outperform Rating	MT
11/12/24	Citigroup Upgrades QuidelOrtho to Buy From Neutral, Raises Price Target to $50 From $44	MT
10/12/24	Jefferies Initiates QuidelOrtho at Hold With $43 Price Target	MT
08/11/24	UBS Cuts Price Target on QuidelOrtho to $43 From $50, Maintains Neutral Rating	MT
08/11/24	RBC Capital Adjusts QuidelOrtho Price Target to $64 From $62, Maintains Outperform Rating	MT
19/09/24	UBS Upgrades QuidelOrtho to Neutral From Sell, Adjusts Price Target to $50 From $42	MT
13/09/24	RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating	MT
05/09/24	QuidelOrtho Shares Rise After Craig-Hallum Upgrade	MT
05/09/24	Craig-Hallum Upgrades QuidelOrtho to Buy From Hold, Adjusts Price Target to $57 From $40	MT
24/06/24	RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	MT
09/05/24	RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	MT
04/03/24	UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	MT
14/02/24	William Blair Downgrades QuidelOrtho to Market Perform From Outperform	MT
14/02/24	Craig-Hallum Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $50 From $158	MT
14/02/24	Citigroup Adjusts Price Target on QuidelOrtho to $50 From $72, Maintains Neutral Rating	MT